Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridisation

Malcolm Anderson(AstraZeneca (United Kingdom)), John F. Beattie(AstraZeneca (United Kingdom)), Gloria A. Breault(AstraZeneca (United Kingdom)), J. Breed(AstraZeneca (United Kingdom)), Kate Byth(AstraZeneca (United Kingdom)), Janet D. Culshaw(AstraZeneca (United Kingdom)), Rebecca Ellston(AstraZeneca (United Kingdom)), Stephen Green(AstraZeneca (United Kingdom)), Claire A. Minshull(AstraZeneca (United Kingdom)), Richard A. Norman(AstraZeneca (United Kingdom)), Richard A. Pauptit(AstraZeneca (United Kingdom)), J. Stanway(AstraZeneca (United Kingdom)), Andrew P. Thomas(AstraZeneca (United Kingdom)), Philip J. Jewsbury(AstraZeneca (United Kingdom))
Bioorganic & Medicinal Chemistry Letters
September 1, 2003
10.1016/s0960-894x(03)00638-3
Cited by 114Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis